NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson will start safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. The health care products maker says it has committed up to $200 million to speed up and expand production of a vaccine program being developed by its Janssen Pharmaceutical Companies. J&J is developing the vaccine with the Danish biotech company Bavarian Nordic.Read more on NewsOK.com